EP1474535A4 - Methodes et compositions pour le traitement du sida et de troubles associes au vih faisant appel a des molecules 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, ou 2045. - Google Patents

Methodes et compositions pour le traitement du sida et de troubles associes au vih faisant appel a des molecules 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, ou 2045.

Info

Publication number
EP1474535A4
EP1474535A4 EP03711004A EP03711004A EP1474535A4 EP 1474535 A4 EP1474535 A4 EP 1474535A4 EP 03711004 A EP03711004 A EP 03711004A EP 03711004 A EP03711004 A EP 03711004A EP 1474535 A4 EP1474535 A4 EP 1474535A4
Authority
EP
European Patent Office
Prior art keywords
hiv
molecules
compositions
methods
related disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03711004A
Other languages
German (de)
English (en)
Other versions
EP1474535A2 (fr
Inventor
Douglas M Powell
Nadine S Weich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of EP1474535A2 publication Critical patent/EP1474535A2/fr
Publication of EP1474535A4 publication Critical patent/EP1474535A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP03711004A 2002-02-15 2003-02-13 Methodes et compositions pour le traitement du sida et de troubles associes au vih faisant appel a des molecules 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, ou 2045. Withdrawn EP1474535A4 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US35739102P 2002-02-15 2002-02-15
US357391P 2002-02-15
US38024902P 2002-05-13 2002-05-13
US380249P 2002-05-13
US39130602P 2002-06-25 2002-06-25
US391306P 2002-06-25
US40629702P 2002-08-27 2002-08-27
US406297P 2002-08-27
US41200702P 2002-09-19 2002-09-19
US412007P 2002-09-19
US41750802P 2002-10-10 2002-10-10
US417508P 2002-10-10
US43231802P 2002-12-10 2002-12-10
US432318P 2002-12-10
PCT/US2003/004246 WO2003070883A2 (fr) 2002-02-15 2003-02-13 Methodes et compositions pour le traitement du sida et de troubles associes au vih faisant appel a des molecules 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, ou 2045.

Publications (2)

Publication Number Publication Date
EP1474535A2 EP1474535A2 (fr) 2004-11-10
EP1474535A4 true EP1474535A4 (fr) 2006-11-08

Family

ID=27761699

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03711004A Withdrawn EP1474535A4 (fr) 2002-02-15 2003-02-13 Methodes et compositions pour le traitement du sida et de troubles associes au vih faisant appel a des molecules 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, ou 2045.

Country Status (5)

Country Link
US (2) US20030216288A1 (fr)
EP (1) EP1474535A4 (fr)
JP (1) JP2005535289A (fr)
AU (1) AU2003215190A1 (fr)
WO (1) WO2003070883A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838742B1 (fr) * 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
WO2005101003A1 (fr) * 2004-04-13 2005-10-27 Bayer Healthcare Ag Diagnostics et therapeutiques de maladies associees au recepteur purinergique 4 type y (p2y4)
WO2006010497A2 (fr) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics et therapeutiques pour des maladies associees a choline kinase (chk)
US20090233985A1 (en) * 2006-07-11 2009-09-17 Urban Scheuring Compositions and methods for inhibiting hiv infections by inhibiting lerepo4 and glipr
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
EP3967143A1 (fr) 2013-02-28 2022-03-16 Hemanext Inc. Dispositif et procede d'addition de gaz pour le traitement sanguin et procédé correspondant
IL299978B1 (en) 2015-03-10 2024-04-01 Hemanext Inc Single-use oxygen reduction kits, devices and methods for their use
KR20240067253A (ko) 2015-04-23 2024-05-16 헤마넥스트 인코포레이티드 혐기성 혈액 저장 용기
MX2017014812A (es) 2015-05-18 2018-05-11 New Health Sciences Inc Metodos para el almacenamiento de sangre completa y composiciones de esta.
CN109195632A (zh) 2016-05-27 2019-01-11 新健康科学股份有限公司 厌氧血液储存和病原体失活方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (fr) * 1999-08-17 2001-02-22 Purdue Research Foundation Traitement de maladies metastatiques
WO2001090328A2 (fr) * 2000-05-24 2001-11-29 Applera Corporation Proteines kinases humaines isolees, molecules d'acides nucleiques codant pour ces proteines, et utilisations de ces dernieres

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492156B1 (en) * 2001-10-31 2002-12-10 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (fr) * 1999-08-17 2001-02-22 Purdue Research Foundation Traitement de maladies metastatiques
WO2001090328A2 (fr) * 2000-05-24 2001-11-29 Applera Corporation Proteines kinases humaines isolees, molecules d'acides nucleiques codant pour ces proteines, et utilisations de ces dernieres

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BADLEY A D ET AL: "UPREGULATION OF FAS LIGAND EXPRESSION BY HUMAN IMMUNODEFICIENCY VIRUS IN HUMAN MACROPHAGES MEDIATES APOPTOSIS OF UNINFECTED T LYMPHOCYTES", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 1, January 1996 (1996-01-01), pages 199 - 206, XP000867519, ISSN: 0022-538X *
DATABASE EMBL [online] 4 April 2001 (2001-04-04), "Homo sapiens serine/threonine kinase FKSG81 (FKSG81) mRNA, complete cds.", XP002400539, retrieved from EBI accession no. EM_HTG:AF348076 Database accession no. AF348076 *
PROUDFOOT A E I ET AL: "CHEMOKINE RECEPTORS-FUTURE THERAPEUTIC TARGETS FOR HIV?", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 57, 1999, pages 451 - 463, XP001121570, ISSN: 0006-2952 *
RYO A ET AL: "Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cells", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 16, no. 10, 1 July 2000 (2000-07-01), pages 995 - 1005, XP002229058, ISSN: 0889-2229 *
RYO A ET AL: "Serial analysis of gene expression in HIV-1-infected T cell lines", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 462, no. 1-2, 26 November 1999 (1999-11-26), pages 182 - 186, XP004260612, ISSN: 0014-5793 *
SCHEURING U J ET AL: "EARLY MODIFICATIONS OF HOST CELL GENE EXPRESSION INDUCED BY HIV-1", AIDS, LONDON, GB, vol. 12, no. 6, 16 April 1998 (1998-04-16), pages 563 - 570, XP008017142, ISSN: 0269-9370 *
SORBARA L R: ET AL: "Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 10, October 1996 (1996-10-01), pages 7275 - 7279, XP002166512, ISSN: 0022-538X *

Also Published As

Publication number Publication date
AU2003215190A8 (en) 2003-09-09
US20030216288A1 (en) 2003-11-20
AU2003215190A1 (en) 2003-09-09
EP1474535A2 (fr) 2004-11-10
WO2003070883A3 (fr) 2004-07-15
US20070031882A1 (en) 2007-02-08
WO2003070883A2 (fr) 2003-08-28
JP2005535289A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
EP1583821A4 (fr) Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
MXPA04004714A (es) Derivados de aril 1,4-pirazina sustituidos.
GB2421434B (en) Compositions And Methods For Treating Gynaecological Disorders
AP2210A (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain.
WO2004058153A9 (fr) Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 3922
EP1567198A4 (fr) Procedes et materiaux destines a traiter des troubles oculaires
EP1470240A4 (fr) Methodes et compositions permettant de traiter les maladies cardio-vasculaires avec les molecules 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747,1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 91
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
AP2147A (en) A composition for treating aids and associated conditions.
EP1583966A4 (fr) Methodes et compositions pour traiter les maladies cardio-vasculaires au moyen de genes 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
AU2002368133A1 (en) 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
IL164887A0 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
TW200503717A (en) Substituted 1,4-pyrazine derivatives
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
EP1471818A4 (fr) Methodes et compositions permettant de traiter les troubles hematologiques au moyen des molecules 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 ou 13249
EP1601799A4 (fr) Procedes et compositions pour le traitement du sida et de troubles lies au vih utilisant les genes 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, ou 46777
EP1472376A4 (fr) Procedes et compositions pour le traitement de troubles urologiques utilisant les molecules 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 ou 6351
EP1697536A4 (fr) Nouveaux oligonucleotides et traitement de troubles cardiaques au moyen de ces oligonucleotides
AU2003202255A1 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
EP1441684A4 (fr) Methodes et compositions de traitement de troubles urologiques utilisant 313, 333, 5464, 18817 ou 33524
AU2002360343A1 (en) Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
AU2002361711A8 (en) Methods and compositions for treating hematological disorders using 252, 304, 19870, 14717, 9941, 19310 and 17832
EP1451364A4 (fr) Methodes et compositions pour le traitement de troubles hematologiques au moyen des genes 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 ou 58874

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040129

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20061010

17Q First examination report despatched

Effective date: 20061211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070622